Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Hememics Biotechnologies, Inc. and General Graphene Corporation Cement Strategic Partnership for Large-Scale Production of Graphene-Based Biosensors

Hememics Biotechnologies, Inc. has entered into a strategic partnership with General Graphene Corporation of Knoxville Tennessee, the culmination of a four-year collaborative effort to develop a scalable, non-clean-room process for the manufacturing of the company’s 32-plex, graphene biosensor chips. Combined with Hememics’ expertise in long-shelf-life detection biology, this partnership promises to revolutionize point-of-care diagnostics tools for pathogens and environmental toxins.

In the past nine months alone, Hememics in conjunction with General Graphene has manufactured more than 100,000 graphene biosensors. Using its patented desiccation technology for detection biology, Hememics has functionalized and tested these biosensors through numerous molecular and antigen tests to detect SEB and ricin at consistent sensitivities in the low picomolar range and get results within 5 minutes.

The 100,000+ sensor tests are part of a broader program for perfecting chip designs. “Feedback from these tests will help a great deal in furthering products targeted for human trials,” said John Warden, CEO of Hememics.

These chips are capable of detecting multiple pathogens from a single saliva or blood sample with a level of detection more than 100x more sensitive than lateral flow, a common point-of-care test format.

“We are more than delighted with the performance of our penny-sized, 32-plex graphene sensor array,” said Sri Aithal, Director of Research and Development at Hememics.

“In the highly competitive world of diagnostics, speed and cost define whole product categories. At single-digit picomolar levels of detection, five-minute test times and non-cleanroom manufacturing techniques, we broke through three significant barriers at once,” said David Ho, President and CSO of Hememics.

“Our collaboration with Hememics has been extremely positive and productive from day one. As a pure-play graphene foundry, General Graphene seeks partners who possess the application expertise necessary to commercialize graphene-based applications. Hememics has been an excellent fit for us with their vast knowledge and expertise in graphene-based biosensors,” said Greg Erickson, CEO of General Graphene.

General Graphene Corporation is a pure-play CVD graphene foundry manufacturing large-area, roll-to-roll (R2R), chemical vapor deposition (CVD) graphene. Using its proprietary roll-to-roll CVD graphene manufacturing processes, General Graphene is equipped to drive meaningful CVD graphene-based R&D at scale and accelerate the commercialization of CVD graphene materials across various markets.

Hememics uniquely uses graphene-based sensors with its patented bio preservatives to bring handheld, lab-quality testing performance to wherever needed – whether it is a farm, emergency room or battlefield. This rugged, low-cost platform consists of a portable, easy-to-use reader utilizing a single-use biochip with 32 sensors that can be individually programmed to detect molecular, antigen and antibody targets. We put a whole lab in your hand so you can make decisions when and wherever necessary – simplifying workflows with results within 5 minutes.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy